Department of Neurology, Xiangcheng People's Hospital, Suzhou, China.
Department of Outpatient, The First Hospital of Jiaxing, Affiliated Hospital of Jiaxing University, Jiaxing, Zhejiang, China.
Biomed Res Int. 2022 Feb 14;2022:1734847. doi: 10.1155/2022/1734847. eCollection 2022.
Glioma is a common tumor originating from the glial cells of the brain. Immune checkpoint inhibitors can potentially be used to treat gliomas, although no drug is currently approved.
The expression levels of the immune checkpoint genes in glioma and normal tissues, and their correlation with the IDH mutation status and complete 1p/19q codeletion, were analyzed using The Cancer Genome Atlas (TCGA) and the Chinese Glioma Genome Atlas (CGGA) databases. Survival analyses were conducted using the CGGA database. Protein-protein interaction and functional enrichment analyses were performed via the STRING database using GO, KEGG, and Reactome pathways. The correlation between the immune checkpoints and the immune cell infiltration was determined using the TISIDB and TIMER databases.
HAVCR2 was overexpressed in the gliomas compared to normal brain tissues, as well as in the high-grade glioma patients and significantly downregulated in IDH mutant or 1p/19q codeletion patients. Overexpression of HAVCR2 was associated with poor survival in tumor grades II, III, and IV and was the most correlated with immune infiltration of B and T cells.
HAVCR2 can be a potential therapeutic target for cancer immunotherapy for glioma patients.
神经胶质瘤是一种起源于脑内神经胶质细胞的常见肿瘤。免疫检查点抑制剂可能可用于治疗神经胶质瘤，但目前尚无药物获批。
利用癌症基因组图谱（TCGA）和中国脑胶质瘤基因组图谱（CGGA）数据库，分析神经胶质瘤和正常组织中免疫检查点基因的表达水平及其与 IDH 突变状态和完全 1p/19q 联合缺失的相关性。利用 CGGA 数据库进行生存分析。利用 STRING 数据库，采用 GO、KEGG 和 Reactome 通路进行蛋白-蛋白相互作用和功能富集分析。利用 TISIDB 和 TIMER 数据库确定免疫检查点与免疫细胞浸润的相关性。
与正常脑组织相比，HAVCR2 在神经胶质瘤中高表达，在高级别神经胶质瘤患者中高表达，在 IDH 突变或 1p/19q 联合缺失患者中低表达。HAVCR2 过表达与肿瘤分级 II、III 和 IV 患者的不良预后相关，与 B 和 T 细胞浸润相关性最强。
HAVCR2 可能成为神经胶质瘤患者癌症免疫治疗的潜在治疗靶点。
